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marketed lapatinib, which has the highest consumption among the most expensive 
drugs in Norway and Slovakia. ConClusions: Countries with lower GDP have less 
availability of anticancer medicines in amount and in quantity. Countries with 
lower GDP must control the usage of drugs for malignancy treatemnt if they want 
to allocated their resurses for treatment of other diseases as well.
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objeCtives: Accurate estimates of the number of advanced (Stage IIIb and Stage 
IV) non-small cell lung cancer (ADV-NSCLC) patients are needed to estimate the 
potential clinical and economic outcomes of new targeted therapies for ADV-NSCLC. 
The objective of this study was to forecast counts of squamous/non-squamous 
cell patients eligible for first- through third-line treatment yearly from 2015-2019 
in EU countries. Methods: Segmented linear regression (“joinpoint”) was used 
to forecast age- and gender-stratified lung cancer incidence rates from histori-
cal (year 2000+) population-based cancer registry data over the next five-years. 
Yearly incident case count totals by country were apportioned according to NSCLC 
morphology and stage at diagnosis. Early to advanced stage progression rates were 
estimated over a 10-year interval. Advanced patients receiving systemic treat-
ment were further stratified by histology and line of treatment to obtain counts. 
A probabilistic sensitivity analysis (PSA) was used to estimate variability in the 
patient counts. Results: By histology, the forecasted number of squamous and 
non-squamous ADV-NSCLC patients receiving first-line treatment in 2015 were: 
Germany = 13,300 and 21,200; UK = 8,400 and 21,300; France = 11,800 and 18,800; 
Italy = 7,600 and 20,500; Spain = 7,100 and 11,400. Combined across both histolo-
gies, the numbers of patients receiving second- and third-line treatment in 2015 
were: Germany = 17,400 and 4,400; UK 15,500 and = 4,000; France = 15,500 and 4,000; 
Italy = 14,600 and 3,800; Spain = 9,400 and 2,400. The projected numbers of deaths 
due to ADV-NSCLC in 2015 were: Germany = 35,300; UK = 27,700; France = 30,800; 
Italy = 27,400; Spain = 19,500. ConClusions: These results represent the first 
published data to estimate the current and future number of patients eligible for 
targeted ADV-NSCLC therapies in the EU-5. Despite declining incidence trends, there 
remains a significant unmet clinical need for ADV-NSCLC treatments to reduce 
high mortality rates.
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the CaNCer drugs FuNd aNd PatieNt aCCes sChemes withiN the uK: 
iNCreased aCCess to oNCology mediCiNes or reduCed value For 
moNey?
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objeCtives: Patient access schemes (PAS) give UK patients access to medicines not 
normally funded by the National Institute for Health and Care Excellence (NICE) and 
balance company profits and competitiveness with government interests to ensure 
availability of medicines at reasonable prices. In April 2011 the NHS payer funded 
Cancer Drugs Fund (CDF) was introduced in England to further improve access to 
life saving cancer medicines not approved by NICE. The objective of this study was 
to determine whether access to new, non-NICE funded oncology medicines contin-
ues to rely on the relatively cost effective PAS or increasingly depends on the more 
costly NHS payer funded CDF. Methods: A search was undertaken for all NICE- or 
Scottish Medicines Consortium (SMC)-approved HTAs incorporating a PAS (PAS-
HTAs) 4 years before and after introduction of the CDF. In addition, all medicines 
approved for use under the CDF were identified. Results: Fifty five of 128 NICE- or 
SMC-approved PAS-HTAs between October 2007 and June 2015 were in oncology. Of 
these, 10 NICE and 4 SMC PAS-HTAs had been approved prior to, whereas 17 NICE 
and 24 SMC PAS-HTAs had been approved after introduction of the CDF, amount-
ing to an almost 6-fold increase in SMC PAS-HTAs but a less than 2-fold increase 
in NICE PAS-HTAs over a similar period. However, 7 oncology medicines receiving 
HTA approval by the SMC but not NICE were included in the May 2015 CDF list of 
approved medicines. ConClusions: Since the introduction of the CDF, there has 
been a discrepancy between the number of PAS-HTAs in cancer treatments between 
NICE and the SMC. For selected medicines, the CDF appears not to have improved 
access to oncology products as part of PAS-HTAs but rather lead to increased costs 
to health service payers.
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objeCtives: The mode by which patients receive information may impact their 
perception of drugs and consequently their compliance. This study aims to meas-
ure how different presentation factors (format - textual, tabular, graphical; order 
of presenting risks and benefits) and patient characteristics can impact percep-
tion of a drug’s risks and benefits. Methods: Data were collected via an online 
questionnaire presenting two drug options to patients in three therapeutic areas: 
atrial fibrillation, breast cancer, diabetes. Two questions were asked on the safety 
and the willingness to take the drug. A novel Generalized Estimating Equation 
method for correlated multinomial data proposed by Touloumis et al., 2013 was 
used to create an ordinal cumulative link model for the questions on perception. 
Factors controlled for were: presentation format, order of presentation of risks and 
benefits, comprehension of drug’s effects by the subject, order of presentation of 
different formats, current mood, and demographic characteristics. Results: Drug 
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objeCtives: The aim of this study was to assess basal cell carcinoma (BCC) 
prevalence in real practice, and to calculate the related healthcare resources 
consumption. Methods: An observational retrospective cohort analysis based 
on administrative databases of three Italian Local Health Units was conducted. 
Beneficiaries who have been hospitalised for BCC (ICD-9 code 173) or with a histo-
logical diagnosis (ICD-O M8090/3-8093/3) from January 1st, 2009 to December 31st, 
2013 - index date - were included. Patients were characterised back to Jan 2009, and 
followed up till the end of the observation period (Dec 2013) to assess healthcare 
resource consumption. Results: According to preliminary findings on around 
550’000 beneficiaries, BCC prevalence through discharge diagnosis was around 6 
cases every 10.000 patients/year; considering also pathological anatomy database, 
10 cases of BCC every 10.000 patients/year were reported. Advanced patients (aBCC) 
were reported to be around 4%, most of them defined according to the following 
criteria: two surgical excisions on the same side and at least one subsequent proce-
dure (surgery, radiotherapy, photodynamic therapy or imiquimod), 0,3% of enrolled 
patients had metastasis.During follow-up, ambulatory surgery was performed in 
63.5% of advanced patients, around 1.6% underwent radiotherapy and 38.1% of 
them had at least one hospital admission; imiquimod was prescribed in 11.1% of 
patients. Yearly aBCC patients resource expenditure was around 404€ for hospitali-
sations - index costs excluded - 32€ for ambulatory care and 77€ for drugs (anti-
inflammatories, antibiotics and topic drugs; 16€ for imiquimod). ConClusions: As 
BCC patients are reported to have a low recurrence of hospitalisations, discharge-
based analysis would underestimate real prevalence. With pathological anatomy 
database, this study estimated 0.4 advanced BCC cases/10’000 beneficiaries/year. 
Healthcare consumption in this sub-population was driven by hospitalisations and 
ambulatory costs due to surgical excision
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objeCtives: Vandetanib, approved in 2012 in Canada, is indicated for the treatment 
of advanced medullary thyroid cancer. QTc-prolongation or torsade de pointes is 
considered in the risk management plan as an identified risk. To minimize this risk 
a restricted distribution program (RDP) has been implemented. Although shown 
effective, there are limited data on its associated burden to patients, health care 
professionals and the healthcare system. The objectives of the present study are 
to evaluate qualitatively and quantitatively the burden associated with the differ-
ent components of the vandetanib RDP and, to determine the economic impact of 
the program for the healthcare system. Methods: A mixed method evaluation 
has been used. Burden was determined by comparing prescribing and monitoring 
practices under the RDP with those that would have been observed in the absence 
of the RDP. Data on healthcare usage were collected through interviews conducted 
in convenient samples of HCPs (prescribers, pharmacists and nurses) either exposed 
to the RDP or not yet certified for the vandetanib RDP (i.e., unexposed) but familiar 
with the treatment of medullary thyroid cancer. A mapping of patient journeys, with 
and without the RDP, was developed to identify major components of the program. 
An economic evaluation, considering the perspective of the third party payers com-
pleted this analysis. Avoidable costs corresponded to those associated with activi-
ties deemed redundant with routine oncology care. Results: Major components 
of the vandetanib RDP have been identified as well as areas of redundancies with 
standard oncology care. For each component, the qualitative burden for HCPs and 
ultimately patients was determined along with its associated costs considering 
the third party payers perspective. ConClusions: Risk minimisation measures 
should avoid duplication of efforts and loss of economic resources. Evaluation of 
burden, key to optimize the effectiveness of risk management plans, should be 
conducted systematically.
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objeCtives: Consumption and expenditure of drugs for malignancy varies between 
countries. One of the main reason is the high price of this innovative drugs. 
Developed countries have more resources for the treatment of malignant diseases 
and better access to expensive drugs than countries with midle income. Methods: 
We compared the data on expenditure and consumption of innovative anticancer 
drugs in middle income country Serbia (13,020 USD), and high income country 
with different GDP: Slovakia (26,497USD) and Norway (64,406 USD) during the year 
2012. Consumption data were expressed in grams of active ingredient per million 
in one year, expenditure in EU. Results: In Norway 144 drugs for malignancy is 
on market, while in Serbia only 92 drugs are available for ttreatemnt of malignancy. 
In Norway in year 2012 440 million eur was spent for drugs for malignancy, or 
about 80 million euros per million inhabitans. Slovakia had more than half lower 
consumption of anticancer medicines, 190 million euros, or about 37 million euros 
per million inhabitants. In Serbia only 73 million euros was spent for anticancer 
drugs, or about 10 million euros per million ihabitants, which is much less com-
pared to the other two countries. Data on consumption 10 most expensive oncology 
drugs, show that the least of these drugs are consumed in Serbia when comparing 
to Norway and Slovakia. Among them, the most frequently used drug in Serbia 
is trastuzumab(treatment of metastatic breast cancer). For this indication is also 
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(Genesis and/or GEDEFO) and health-economists (universities/public entities). 
The questionnaire consisted of 36 items with a Likert rating scale of 9 points (9 
= full agreement). Consensus was considered when more than two-thirds of the 
responses were in the same tercile. Results: A total of 101 experts where invited 
(40.6% oncologists; 44.6% hospital pharmacists and 14.8% health-economists). 
81% and 67% questionnaires were retrieved in the first and second round, respec-
tively. Only two rounds were required as variability was less than 10% (delta CV 
7.1%). Internal consistency of the questionnaire was high (α C: 0.886), as was the 
correlation between the rounds (R of Spearman: 0.946) Consensus was attained 
in 29 items. Most experts agreed on: i) the need to improve scales and quality 
of life-related measurements (96%, CI95%= 90.7-98.8%); ii) the need for Health 
Authorities to define a cost-effectiveness threshold (91%, CI95%= 84.5-97.9%) and 
if a different one for “end of life treatments” is required (81%, CI95%= 71.7-90.3%); 
iii) the importance of considering cost-effectiveness data along with the budget 
impact of oncologic therapies (97%, CI95%= 93.1-99,0%); iv) the need to consider 
the societal perspective in the assessment of advanced cancer treatments (94%, 
CI95%= 88.5-99.7%). Lack of consensus was observed regarding the use of mean or 
median overall survival as best efficacy variable for IO therapies ConClusions: 
Consensus in both clinical and pharmaco-economic aspects was high among the 
different health professionals. Lack of agreement in specific questions suggests 
the need for further research on these new therapeutic options.
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objeCtives: In patients with bone metastases from solid tumours, denosumab 
(Dmab) subcutaneous (SC) injection represents an alternative formulation to zole-
dronic acid (Zol) intravenous (IV) infusion with a superior efficacy for skeletal-related 
events prevention. This observational Time and Motion study estimated treatment 
duration endpoints associated with Dmab SC injection and Zol IV use as monother-
apy. Methods: In the ambulatory setting of 3 Belgian hospitals, patients with bone 
metastases from solid tumours were observed during administration of SC Dmab 
or Zol IV. The following pre-defined tasks were recorded in military time: patient 
registration, drug preparation, IV catheter installation (one site additionally included 
routine blood sampling), IV/SC drug administration (IV: infusion connection until 
disconnection; SC: syringe filling and injection), material disposal, and post-treatment 
monitoring. Active healthcare professional (HCP) time associated with aforemen-
tioned pre-defined tasks was recorded using a stopwatch. Time endpoints measured 
for each treatment were total task time, total active HCP time, drug administration 
duration, and patient chair time. Data (mean) were analyzed per site and pooled using 
a random intercept model. Results: 44 Dmab SC and 29 Zol IV observations were 
collected. Pooled data across sites showed a mean duration of Dmab SC injection of 
1.4 minutes (min) and 29 min for Zol IV (95% time reduction). The mean total tasks 
time was 10.3 min for SC Dmab and 49.2 min for IV Zol (-79%). When Dmab SC was 
used, active HCP time was decreased by 54% (6.5 min for SC Dmab vs. 14.2 min for 
Zol IV). Mean patient chair time was 12.2 min for SC Dmab and 60.5 min for IV Zol 
(-80%). ConClusions: Dmab SC injection was associated with time savings in all 
endpoints measured. Using SC Dmab administration instead of Zol infusion could 
improve patient comfort and free up hospital capacity to treat patients in Belgium.
PCN312
results From a time aNd motioN study oF deNosumaB suBCutaNeous 
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objeCtives: Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available 
as a superior treatment option in patients with bone metastases from solid tumours, 
compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. 
Although Zol was the mainstay treatment for skeletal-related events prevention, 
Dmab provides an alternative formulation to IV infusions. This Time and Motion 
study was conducted in Italy to estimate treatment duration endpoints associated 
with Dmab SC and Zol IV use. Methods: Patients with bone metastases from solid 
tumours scheduled to receive Dmab SC or Zol IV monotherapy in the outpatient 
setting of 5 Italian hospitals were included. The following pre-defined tasks were 
recorded in military time: patient registration, IV catheter installation, IV/SC drug 
administration (IV: infusion connection until disconnection; SC: syringe filling and 
injection), and post-treatment monitoring. Active healthcare professional (HCP) time 
was recorded using a stopwatch. Time endpoints were total task time, total active 
HCP time, drug administration duration, and patient chair time. Data (mean) were 
analysed per site and pooled by country using a random intercept model. Results: 
A total of 85 observations were collected (50 Dmab SC and 35 Zol IV). Across sites, 
mean administration duration of Dmab SC was 3.4 minutes (min) and 15.9 min for 
Zol IV (-78%). The mean total task time was 9.9 min for Dmab SC and 31.2 min for Zol 
IV (-68%). Time savings associated with Dmab SC versus Zol IV were also reflected 
in the total active HCP time (7.2 min vs. 12.1 min, -41%) and patient chair time (8.1 
perception was highly modified by a number of factors, most significantly order of 
presentation of risks and benefits and comprehension of a drug’s risks and benefits. 
Showing the favourable effects first could halve the odds ratio of a more nega-
tive score, with all other factors held constant. Better comprehension always led 
to more positive perception. Other significant factors included negative mood at 
time of answering and number of other formats already shown, both leading to 
more negative answers. Impact of presentation type was highly dependent on the 
therapeutic area. ConClusions: The perception of a drug’s benefit-risk can be 
heavily impacted by how it is presented to the patient. These results underline the 
importance of using an understandable presentation format in the communication 
of benefits and risks of drugs in order to support patients to make informed deci-
sions regarding their treatment choice.
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objeCtives: Between 10 and 29% of lung cancer (LC) are supposed to be attribut-
able to occupational exposures. However, LC of occupational origin remains under-
reported. To improve the identification and compensation of occupational LC, we 
implemented at the Léon-Bérard Cancer Centre, a questionnaire-based process to 
systematically identify LC patients potentially exposed at the workplace and to be 
seen in an “occupational cancer” consultation. Selection was based on patients’ 
reporting of exposure to carcinogens or potentially exposed occupations. The aim 
of this study was to assess the cost of this innovative program. Methods: The 
cost assessment was performed prospectively. Three situations were analyzed: 
questionnaire returned by the patient (up to one reminder), consultation required 
(situation 1), questionnaire returned (up to one reminder), no consultation 
required (situation 2), questionnaire not returned (up to one reminder) (situation 
3). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Data on consumption of resources were collected from 
the questionnaire administration until the physician evaluation and occupational 
cancer declaration if any. Uncertainty was captured by one-way and probabilistic 
sensitivity analyses using a non-parametric bootstrap method. All costs were 
given in 2014 euros. Results: 310 patients were enrolled from March 2014 to 
May 2015. 9 patients without lung cancer were excluded. The measured costs per 
patient were in average € 179 (SD: 53) for situation 1 (n= 77), 40€ (SD 16) for situation 
2 (n= 82), and € 24 (SD: 7) for situation 3 (n= 142). Sensitivity analyses showed that 
the unit costs of physician and duration of consultations had a major role in the 
process’ costs. ConClusions: The implementation of our approach increased the 
identification and the compensation of occupational lung cancer. Our approach 
responds to the objectives of the National Cancer Plan and helps to improve the 
overall care of patients with cancer.
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objeCtives: The number of patients seeking cancer information over the internet 
is increasing. However, it is unknown what kind of information sources is available 
online in Japan, UK and USA. The objective of the study is to evaluate the informa-
tion sources related to breast cancer and to compare the information source among 
Japan, UK and USA. Methods: We identified top-rated 20 information sites and 
the number of advertisements on the initial screen by using a key word as “Breast 
cancer” on Yahoo and Google sites in Japan, UK and USA. Information sources were 
defined and categorized into six kinds of information organizers; public institutes, 
academic associations, NGO/NPOs, information portal, advertisements, and corpo-
rate sponsored sites. The each information source was categorized by two evalu-
ators independently. Third evaluator reconciled and decided the category of the 
information source if evaluation results were not identical between two evaluators. 
The proportion of internet sources by six categories was calculated and compared 
among three countries. Results: In Japan, the proportion of information sources 
by public institutions and academic associations was 30%. Less than 10% of infor-
mation sources were by NGO/NPOs. More than half of information sources were 
advertisements. In UK, 70% of information sources were provided by NGO/NPOs 
whereas less than 20% of information sources were advertisement. In USA, 30% 
of information sources were by academic institutions whereas more than 50% of 
information sources were by information portal. ConClusions: This comparative 
survey provides an overview of information sources related to breast cancer avail-
able on the internet. The number of top-rated information sites by public institutes, 
academic associations was low compared to UK and USA. There were a few informa-
tion sources by NGO/NPO in Japan.
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objeCtives: Clinical and health-economic criteria to accurately assess the 
value of new immuno-oncology (IO) drugs are currently undetermined. The aim 
of this study was to assess the current knowledge about these criteria among 
the Spanish scientific community. Methods: The Delphi method was used to 
survey a multi-disciplinary group of Spanish oncologists [melanoma, lung, or 
genitourinary-specialists (hospital/regional managers)], hospital pharmacists 
